These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37811572)

  • 1. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials.
    Rotstein C; Lynch JP; Zhanel GG
    Expert Rev Anti Infect Ther; 2023 Oct; ():1-13. PubMed ID: 37811572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Kidd JM; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
    Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
    Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
    Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
    Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
    Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
    J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
    Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
    Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Naik J; Puzniak L; Critchlow S; Elsea D; Dillon RJ; Yang J
    Infect Dis Ther; 2021 Jun; 10(2):939-954. PubMed ID: 33837518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
    Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
    Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
    Paterson DL; Bassetti M; Motyl M; Johnson MG; Castanheira M; Jensen EH; Huntington JA; Yu B; Wolf DJ; Bruno CJ
    J Antimicrob Chemother; 2022 Aug; 77(9):2522-2531. PubMed ID: 35781341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
    Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
    Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    Jones RN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Jul; 79(1):60-69. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.